Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that it has executed an exclusive agreement with EO Medical Pte Ltd to distribute its HearTwave II System and proprietary Microvolt T-Wave Alternans™ (MTWA) software and Micro-V Alternans Sensors in Singapore upon regulatory approval.
“We look forward to gaining regulatory approval in Singapore, which we expect will occur within the next six to nine months, and begin marketing our MTWA technology.”
EO Medical is a leading supplier of cutting-edge and innovative medical devices to healthcare providers. This addition is in-line with the Company's strategy of partnering with companies that have established distribution networks, to make its technology readily available in cardiology and internal medicine physician practices and in hospitals.
"This is a great opportunity for the Company that will incrementally add to our global presence," said Ali Haghighi-Mood, Cambridge Heart CEO. Mr. Haghighi-Mood added, "We look forward to gaining regulatory approval in Singapore, which we expect will occur within the next six to nine months, and begin marketing our MTWA technology."
Sudden Cardiac Arrest (SCA) is the leading cause of death in the U.S. accounting for an estimated 300,000 deaths each year - more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8 percent, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients in the U.S. who can benefit from annual MTWA testing. Microvolt T-Wave Alternans is a marker of SCA risk which is measured during a non-invasive treadmill test using Cambridge Heart's proprietary technologies. The Company's MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy.
Research reveals undertreatment of women with heart disease